<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Demand is rising for multi-parameter polypills that improve adherence and manage cardiometabolic risk, driven by digital pharmacies, generics, advanced formulations and Asia-Pacific uptake.Dublin, Aug. 25, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/report/global-polypill-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4ddhfw&amp;utm_campaign=2336743+-+Polypill+Products+Market+(2026-2031)+-+Rising+Cardiovascular+Disease+Burden+and+Need+for+Improved+Medication+Adherence+to+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Polypill Products - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Polypill Products - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. Global Polypill Products Market to Reach USD 38.82 Billion by 2031 as Cardiovascular and Metabolic Disease Burden Rises The global polypill products market is projected to grow from USD 33.41 billion in 2025 to USD 34.18 billion in 2026, reaching USD 38.82 billion by 2031. The market is forecast to expand at a compound annual growth rate of 2.58% from 2026 to 2031, supported by the rising prevalence of cardiovascular disease, type 2 diabetes and related metabolic conditions. Demand for polypill products is increasing as healthcare systems seek to improve medication adherence, reduce treatment complexity and lower the risk of cardiovascular events. Cardiovascular disease and type 2 diabetes co-occur in approximately 30% of patients in high-burden regions, strengthening demand for fixed-dose combination therapies that address multiple risk factors through a single daily treatment. Cardiovascular and Metabolic Disease Trends Support Market Growth Clinical evidence continues to reinforce the role of polypills in cardiovascular disease prevention and diabetes-linked cardiovascular risk reduction. Meta-analyses published in 2025 reported reductions of between 22% and 29% in major adverse cardiovascular events among polypill users compared with patients receiving usual care. The World Health Organization's 2025 Model List of Essential Medicines endorsed GLP-1 receptor agonists for patients with diabetes and coexisting cardiovascular or kidney disease. This development supports broader interest in cardiometabolic fixed-dose combinations. Regulatory authorities in the United States and Europe are also placing greater emphasis on treatment adherence and persistence as patient-centered endpoints, potentially supporting more efficient reviews when manufacturers provide compelling real-world evidence. Economic evaluations further strengthen the market outlook. The incremental cost per quality-adjusted life year for a primary-prevention polypill has been estimated at USD 8,560, remaining below commonly applied willingness-to-pay thresholds across OECD markets. Improved Medication Adherence Drives Polypill Adoption Adherence to multi-pill cardiovascular treatment regimens frequently declines below 60% after one year. In contrast, the SECURE randomized trial recorded 86% adherence among patients receiving a polypill and reported a 24% reduction in cardiovascular events. Digital health tools are also contributing to stronger persistence. Patient-support programs that combine fixed-dose therapies with SMS reminders have improved refill rates by approximately 15% to 20% compared with conventional retail benchmarks. In India, some online pharmacies are integrating medication subscriptions, teleconsultations and remote blood-pressure monitoring, helping clinicians adjust therapy while supporting continued treatment. These adherence improvements may create value for healthcare systems by reducing avoidable hospitalizations, complications and productivity losses. Regulatory guidance from the European Medicines Agency also recognizes real-world adherence evidence as relevant to the assessment of combination products. Regulatory Complexity Remains a Key Market Restraint Despite the favorable clinical outlook, multi-ingredient products face demanding development and approval requirements. Manufacturers may need to conduct separate bioequivalence studies for multiple dose strengths, increasing costs and extending development timelines. Products intended for tropical markets also require extensive stability testing and specialized moisture-resistant packaging, particularly when active ingredients are sensitive to high temperatures and humidity. The U.S. Food and Drug Administration cleared Widaplik following an accelerated stability program and a 500-patient bioequivalence study. Regulatory differences between markets remain a challenge because existing international guidelines do not comprehensively address interactions among multiple active ingredients. Additional constraints include limited dosing flexibility, clinician reluctance to adopt fixed combinations in selected patient groups and complex intellectual-property requirements. Multi-Parameter Polypills Expected to Outpace the Overall Market Multi-parameter polypills are forecast to expand at a 3.06% CAGR, exceeding the growth rate of the overall polypill products market. The CNIC-Polypill, offered in six dose combinations, illustrates how multilayer tablet technology can address incompatibilities among active ingredients. Clinical findings indicate approximately 7% additional LDL-cholesterol reduction when atorvastatin and ramipril are administered together. Single-parameter polypills accounted for 66.02% of market revenue in 2025, reflecting their earlier regulatory approvals and compatibility with established hospital treatment protocols. However, evidence from the SECURE and PolyIran-Liver studies is supporting the development of products containing three or more therapeutic components. Advances in coated pellet cores, multilayer compression and hot-melt extrusion are also helping manufacturers overcome formulation barriers. North America Leads While Asia-Pacific Records the Fastest Growth North America generated 41.36% of global polypill products market revenue in 2025. Growth is supported by high hypertension prevalence, broad insurance coverage and early approval of triple-component therapies such as Widaplik. Canada follows similar regulatory and intellectual-property pathways, while adoption in Mexico remains at an earlier stage. Asia-Pacific is projected to register the fastest regional growth, with a 6.27% CAGR through 2031. China's volume-based procurement policies are expanding access through public hospitals, while India's Production Linked Incentive scheme is encouraging domestic manufacturing of multi-parameter formulations. Japan and South Korea have reduced patient co-payments for approved polypills, contributing to higher prescription volumes. Europe also presents favorable opportunities as reimbursement authorities increasingly account for adherence improvements in health-economic assessments. In parts of Africa and Latin America, donor-supported access programs are widening availability, although distribution and packaging costs remain significant in hot and humid climates. Overall, the polypill products market is positioned for steady expansion as clinical evidence, adherence benefits, digital patient support and healthcare cost considerations encourage wider adoption. Continued progress in formulation technology and regulatory harmonization will be important to unlocking the full potential of fixed-dose combination therapies through 2031. Key Topics Covered: 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Prevalence of Cardiovascular &amp; Metabolic Diseases 4.2.2 Improved Adherence &amp; Pill-Burden Reduction with FDCs 4.2.3 Inclusion of Key FDCs in WHO EML &amp; Clinical Guidelines 4.2.4 Aging Population Driving Cost-Effective Polypharmacy 4.2.5 3-D Printing Enables Personalized, On-Demand Polypills 4.2.6 LMIC Public-Procurement Schemes Boosting Bulk Uptake 4.3 Market Restraints 4.3.1 Regulatory Complexity for Multi-API Approvals 4.3.2 Limited Dosing Flexibility Reduces Clinician Uptake 4.3.3 Patent-Price &amp; Reimbursement Pressures 4.3.4 Stability Challenges in Hot/Humid Supply Chains 4.4 Regulatory Landscape 4.5 Technological Outlook 4.6 Porter's Five Forces Analysis 4.6.1 Threat of New Entrants 4.6.2 Bargaining Power of Buyers 4.6.3 Bargaining Power of Suppliers 4.6.4 Threat of Substitute Products 4.6.5 Intensity of Competitive Rivalry 5 Market Size &amp; Growth Forecasts 5.1 By Product Type 5.1.1 Single-Parameter Polypills 5.1.2 Multi-Parameter Polypills 5.2 By Application 5.2.1 Cardiovascular Disease Prevention 5.2.2 Diabetes-linked CV Risk Reduction 5.2.3 Other Therapeutic Areas 5.3 By Distribution Channel 5.3.1 Hospital Pharmacies 5.3.2 Retail Pharmacies 5.3.3 Online Pharmacies 5.4 By Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East &amp; Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East &amp; Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products &amp; Services, and Recent Developments) 6.3.1 Abbott Laboratories 6.3.2 AstraZeneca 6.3.3 Aurobindo Pharma 6.3.4 Bayer 6.3.5 Cadila Pharmaceuticals 6.3.6 Cipla, Inc. 6.3.7 Dr. Reddy's Laboratories 6.3.8 GlaxoSmithKline 6.3.9 Grupo Ferrer 6.3.10 Hikma Pharmaceuticals 6.3.11 Intas Pharmaceuticals 6.3.12 Johnson &amp; Johnson (Janssen) 6.3.13 Lupin 6.3.14 Merck &amp; Co. 6.3.15 Novartis 6.3.16 Pfizer 6.3.17 Sanofi 6.3.18 Servier 6.3.19 Sun Pharma 6.3.20 Teva Pharmaceutical Industries 6.3.21 Torrent Pharma 6.3.22 Viatris 7 Market Opportunities &amp; Future Outlook 7.1 White-space &amp; Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/report/global-polypill-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4ddhfw&amp;utm_campaign=2336743+-+Polypill+Products+Market+(2026-2031)+-+Rising+Cardiovascular+Disease+Burden+and+Need+for+Improved+Medication+Adherence+to+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/3ub83e</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MTAzYzhjNmEtOGQ3MC00OTJmLWJhMWUtN2RmODVmNmI5MzI3LTEwMjY3MzctMjAyNi0wOC0yNS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Polypill Products Market (2026-2031) - Rising Cardiovascular Disease Burden and Need for Improved Medication Adherence to Drive Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn